Navigation Links
GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
Date:8/30/2010

garding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.

Valeant Pharmaceuticals Forward-Looking Statement

This press release may contain forward-looking statements, including, but not limited to, statements regarding the review by the FDA with respect to, and the timing of, any marketing approval for ezogabine. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC"). Forward-looking information contained in this press release does not take into account or give effect to the impact of the proposed merger with Biovail.  Additional uncertainties relating to the proposed merger with Biovail are discussed under the heading "Risk Factors" in the definitive joint proxy statement/prospectus contained in the Schedule 14A filed by Valeant on August 23, 2010  with the SEC.  Readers are cautioned not to place undue reliance on
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  IRIDEX Corporation (NASDAQ: IRIX ... and full year 2014 financial results after the market closes ... the release, the Company will host a conference call with ... Thursday, March 5, 2015 to discuss the ... Interested parties may access the live conference call via telephone ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and ... consumers, employers and government health plans $23.3 ... released by the Pharmaceutical Care Management Association (PCMA). ... drugs offers one of the easiest ways to ... Mark Merritt . "Policymakers should resist efforts ...
(Date:2/26/2015)... -- Every year many millions of donations are obtained ... year after year doctors and the medical profession continue ... to determine the status of heart health in all ... though that technology is over 100 years old, ... (while most patients do not know) that EKG,s, in ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2
... as Marker of,Treatment Success -, SAN FRANCISCO, ... presented at the 59th Annual Meeting of,the American ... shows that,PEGASYS(R) (peginterferon alfa-2a) treatment regimens result in ... patients as,compared to regimens with another pegylated interferon.(1), ...
... Denmark, October 31 , - DoctorConsult in ... Improve Clinician Decision Making and Health Care Business,Performance, ... and more than a,century of experience as a ... provide interactive clinical reference and clinical decision,support (CDS) ...
Cached Medicine Technology:New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7Elsevier is Expanding eClinical Solutions in Europe 2Elsevier is Expanding eClinical Solutions in Europe 3
(Date:2/27/2015)... Wisconsin (PRWEB) February 27, 2015 Dr. ... plastic surgeons , is pleased to announce the expansion ... now open in Delafield. Quintessa has begun seeing patients ... the new Delafield location will offer a variety of ... including: Botox, filler injectables, micro laser peels, chemical peels, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 On February 24 ... Real Liquid Botox ,” that details the development of ... is working its way through FDA trials. For those afraid ... cream is very attractive. Of course, if the drug ultimately ... at a physician’s office. (see: goo.gl/PQvQwk) , “As the article ...
(Date:2/27/2015)... Beach, FL (PRWEB) February 27, 2015 ... medical companies, devices and pharmaceuticals, Benedict Advertising & ... as its newest client. The company’s patented NITROUSEAL® ... a pain-free, no-stress method of sedation. , Sedation ... medical patient comfort to a new level, though ...
(Date:2/27/2015)... February 27, 2015 The winter season is ... and expansion. When mold grows, it can be harmful to ... to avoid the consequences of mold growth with the help ... is offering tips on the best ways to prevent mold ... which makes perfect conditions for mold to thrive. Mold must ...
(Date:2/27/2015)... 2015 Victorian Hotel recently celebrated Valentine’s ... who wanted to spend the auspicious day together. This ... a jump on Valentine’s Day with a sweet overnight ... of their luxurious rooms. , The hotel started ... for a mouthwatering 3 course meal at Café 335. ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Is Topical Botox the Next Big Thing? 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2
... of asthma-causing immune molecules Asthma and ... Soluble IgE molecules, produced by immune cells known as ... Therapeutic targeting of IgE in the blood can neutralize ... allergic asthma. However, this approach does not halt IgE ...
... was worse than physical abuse alone, study found , MONDAY, ... finds that older women who are exposed to physical and ... twist did show up in the results, study author Dr. ... more damaging than physical abuse alone. , Why? "The physical ...
... be wise, expert says, , MONDAY, May 10 (HealthDay ... its authors describe as a precise description of the ... heart-related fats. , It provides "the best evidence yet ... blood lipids profile," said Dr. Joan Sabate, who chairs ...
... ... Beard & Arsenault in Louisiana says the estimated 5,000 U.S. deaths each year from ... the most part preventable.” , ... Alexandria, LA (PRWEB) May 10, 2010 – Louisiana’s Department of Health and ...
... - The Massachusetts Eye and Ear Infirmary, Harvard Medical ... renewal from the National Institutes of Health, National Eye ... scientists to promote translational and clinical research into cures ... five-year K12 grant to Mass. Eye and Ear (representing ...
... ... ... E. Clyburn will give the commencement address at the 135th Commencement ceremony for Meharry Medical ... Lipscomb University in the Allen Arena. Doors open at 11:30 a.m., , , , ,Congressman Clyburn ...
Cached Medicine News:Health News:JCI online early table of contents: May 17, 2010 2Health News:JCI online early table of contents: May 17, 2010 3Health News:JCI online early table of contents: May 17, 2010 4Health News:JCI online early table of contents: May 17, 2010 5Health News:JCI online early table of contents: May 17, 2010 6Health News:JCI online early table of contents: May 17, 2010 7Health News:JCI online early table of contents: May 17, 2010 8Health News:Older, Abused Women Suffer Poor Mental Health 2Health News:Eating Nuts May Help Cholesterol Levels 2Health News:Eating Nuts May Help Cholesterol Levels 3Health News:Food Poisoning Suspected in 3 Deaths, 40 Illnesses at Central State Hospital in Pineville, LA 2Health News:Mass. Eye and Ear receives NEI grant renewal for 'growing' clinical/scientists 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 3
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Classic proven design with superior clinical results...
... Using high-performance materials contributes to ... addition to surgical procedures and technique, ... great bearing on your patients' outcomes, ... DePuy developed MARATHON Cross-Linked Polyethylene. MARATHON ...
Medicine Products: